You are here

Nat Biotechnol DOI:10.1038/nbt.2940

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

Publication TypeJournal Article
Year of Publication2014
AuthorsYuan, Y, Van Allen, EM, Omberg, L, Wagle, N, Amin-Mansour, A, Sokolov, A, Byers, LA, Xu, Y, Hess, KR, Diao, L, Han, L, Huang, X, Lawrence, MS, Weinstein, JN, Stuart, JM, Mills, GB, Garraway, LA, Margolin, AA, Getz, G, Liang, H
JournalNat Biotechnol
Volume32
Issue7
Pages644-52
Date Published2014 Jul
ISSN1546-1696
KeywordsBiomarkers, Tumor, Databases, Genetic, DNA, Neoplasm, Genetic Markers, Genetic Predisposition to Disease, Humans, Neoplasms, Prevalence, Proteome, Risk Assessment, Survival Analysis
Abstract

Molecular profiling of tumors promises to advance the clinical management of cancer, but the benefits of integrating molecular data with traditional clinical variables have not been systematically studied. Here we retrospectively predict patient survival using diverse molecular data (somatic copy-number alteration, DNA methylation and mRNA, microRNA and protein expression) from 953 samples of four cancer types from The Cancer Genome Atlas project. We find that incorporating molecular data with clinical variables yields statistically significantly improved predictions (FDR

URLhttp://dx.doi.org/10.1038/nbt.2940
DOI10.1038/nbt.2940
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/24952901?dopt=Abstract

Alternate JournalNat. Biotechnol.
PubMed ID24952901
PubMed Central IDPMC4102885
Grant ListP30 CA016672 / CA / NCI NIH HHS / United States
P50 CA100632 / CA / NCI NIH HHS / United States
CA143883 / CA / NCI NIH HHS / United States
CA016672 / CA / NCI NIH HHS / United States
P50 CA098258 / CA / NCI NIH HHS / United States
T32 CA009172 / CA / NCI NIH HHS / United States
CA175486 / CA / NCI NIH HHS / United States
R01 CA175486 / CA / NCI NIH HHS / United States
U24 CA143883 / CA / NCI NIH HHS / United States